Prescription Drug Abuse: Executive Summary of a Policy Position Paper From the American College of Physicians
Authors: Neil Kirschner, Jack Ginsburg, Lois Snyder Sulmasy
Journal: Annals of Internal Medicine (2013)

Position Papers4 February 2014Prescription Drug Abuse: Executive Summary of a Policy Position Paper From the American College of PhysiciansNeil Kirschner, PhD, Jack Ginsburg, and Lois Snyder Sulmasy, JD, for the Health and Public Policy Committee of the American College of Physicians*Neil Kirschner, PhDFrom the American College of Physicians, Philadelphia, Pennsylvania., Jack GinsburgFrom the American College of Physicians, Philadelphia, Pennsylvania., and Lois Snyder Sulmasy, JDFrom the American College of Physicians, Philadelphia, Pennsylvania., for the Health and Public Policy Committee of the American College of Physicians*Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M13-2209 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The inappropriate use and abuse of prescription drugs is a serious public health problem. The Centers for Disease Control and Prevention (CDC) has declared that the United States is in the midst of an epidemic of deaths from prescription drug overdose (1). The CDC reports that drug overdose, particularly due to the increase in nonmedical use of prescription pain-relief drugs, is the second leading cause of deaths from unintentional injuries in the United States, exceeded only by motor vehicle fatalities (2). A recent analysis of preliminary CDC data suggests that drug overdose may now be the leading cause of such ...References1. Government Accountability Office. Prescription Pain Reliever Abuse. GAO-12-115, December 2011. Accessed at www.gao.gov/assets/590/587301.pdf on 31 May 2013. Google Scholar2. Centers for Disease Control and Prevention. Unintentional drug poisoning in the United States. July 2010. Accessed at www.cdc.gov/homeandrecreationalsafety/pdf/poison-issue-brief.pdf on 31 May 2013. Google Scholar3. Girion L, Glover S. Preventable deaths from drugs, motor vehicles and firearms. Los Angeles Times. July 23, 2012. Accessed at http://graphics.latimes.com/fever-drug-death-chart/ on 31 May 2013. Google Scholar4. Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health: summary of national findings. NSDUH Series H-41, HHS publication no. (SMA) 11-4658. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011. Accessed at http://oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.htm#2.16 on 31 May 2013. Google Scholar5. Partnership for a Drug-Free America and MetLife Foundation. 2010 partnership attitude tracking study. April 6, 2011. Accessed at www.drugfree.org/wp-content/uploads/2011/04/FULL-REPORT-FINAL-PATS-Teens-and-Parent-April-6-2011-1.pdf on 31 May 2013. Google Scholar6. Lembke A. Why doctors prescribe opioids to known opioid abusers. N Engl J Med. 2012;367:1580-1581. [PMID: 23363516] CrossrefMedlineGoogle Scholar7. National Institute on Drug Abuse. Commonly abused prescription drugs chart. Updated October 2011. Accessed at www.drugabuse.gov/drugs-abuse/commonly-abused-drugs/commonly-abused-prescription-drugs-chart on 31 May 2013. Google Scholar8. Centers for Disease Control and Prevention. Opioids drive continued increase in drug overdose deaths. February 20, 2013. Accessed at www.cdc.gov/media/releases/2013/p0220_drug_overdose_deaths.html on 31 May 2013. Google Scholar9. National Institute on Drug Abuse. Research reports: prescription drugs: abuse and addiction. Chronic pain treatment and addiction. Updated October 2011. Accessed at www.drugabuse.gov/publications/research-reports/prescription-drugs/chronic-pain-treatment-addiction on 31 May 2013. Google Scholar10. National Institute on Drug Abuse. Topics in brief: drug abuse prevention. Accessed at www.drugabuse.gov/publications/topics-in-brief/drug-abuse-prevention on 31 May 2013. Google Scholar11. Snyder L; American College of Physicians. American College of Physicians Ethics Manual: sixth edition. Ann Intern Med. 2012;156:73-104. [PMID: 22213573] LinkGoogle Scholar12. Chou R, Fanciullo G, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113-130. [PMID: 19187889] CrossrefMedlineGoogle Scholar13. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: National Acad Pr; 2011. Google Scholar14. Furrow BR. Pain management and provider liability: no more excuses. J Law Med Ethics. 2001;29:28-51. [PMID: 11521268] CrossrefMedlineGoogle Scholar15. National Institute on Drug Abuse. Topics in Brief: prescription drug abuse. Revised December 2011. Accessed at www.drugabuse.gov/publications/topics-in-brief/prescription-drug-abuse on 31 May 2013. Google Scholar16. Barrett SP, Meisner JR, Stewart SH. What constitutes prescription drug misuse? Problems and pitfalls of current conceptualizations. Curr Drug Abuse Rev. 2008;1:255-62. [PMID: 19630724] CrossrefMedlineGoogle Scholar17. Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-44, HHS publication no. (SMA) 12-4713. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012. Accessed at http://oas.samhsa.gov/NSDUH/2k10NSDUH/2k10Results.htm#2.16. on 31 May 2013. Google Scholar18. Substance Abuse and Mental Health Services Administration. National survey shows reduction in non-medical prescription drug use among young adults [press release]. 24 September 2012. Accessed at www.samhsa.gov/newsroom/advisories/1209244622.aspx on 31 May 2013. Google Scholar19. Farber J, Gabler E. Narcotic pain killer use booming in elderly. Medpage Today. 30 May 2012. Accessed at www.medpagetoday.com/Geriatrics/PainManagement/32967 on 31 May 2013. Google Scholar20. Culberson JW, Ziska M. Prescription drug misuse/abuse in the elderly. Geriatrics. 2008;63:22-31. [PMID: 18763848] MedlineGoogle Scholar21. National Institute on Drug Abuse. Prescription drugs: abuse and addiction. Older adults. Accessed at www.drugabuse.gov/publications/research-reports/prescription-drugs/trends-in-prescription-drug-abuse/older-adults on 31 May 2013. Google Scholar22. Tudor CG. Appendix C. Analysis of Morphine Equivalent Dose (MED) in the Medicare Part D Program. Letter to All Part D Sponsors. Supplemental guidance related to improving drug utilization review controls in Part D. 6 September 2012. Accessed at www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/HPMSSupplementalGuidanceRelated-toImprovingDURcontrols.pdf on 31 May 2013. Google Scholar23. Wunsch MJ, Nakamoto K, Behonick G, Massello W. Opioid deaths in rural Virginia: a description of the high prevalence of accidental fatalities involving prescribed medications. Am J Addict. 2009;18:5-14. [PMID: 19219660] CrossrefMedlineGoogle Scholar24. Paulozzi LJ, Xi Y. Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiol Drug Saf. 2008;17:997-1005. [PMID: 18512264] CrossrefMedlineGoogle Scholar25. Kiely K. GAO report: Millions in fraud, drug abuse clogs Medicaid. USA Today. 30 September 2009. Accessed at http://usatoday30.usatoday.com/news/health/2009-09-29-Medicaid-drug-abuse-fraud-Michael-Jackson_N.htm on 31 May 2013. Google Scholar26. Kaiser Family Foundation. Prescription drug trends fact sheet: May 2010 update. Accessed at www.kff.org/rxdrugs/upload/3057-08.pdf on 31 May 2013. Google Scholar27. Nelson LS, Perrone J. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS). JAMA. 2012;308:457-8. [PMID: 22851109] CrossrefMedlineGoogle Scholar28. Alexander GC, Kruszewski SP, Webster DW. Rethinking opioid prescribing to protect patient safety and public health. JAMA. 2012;308:1865-6. [PMID: 23150006] CrossrefMedlineGoogle Scholar29. Veterans Health Administration, Acute Care Strategic Health Care Group and Geriatric/Extended Care Strategic Health Care Group. Pain Assessment, the 5th Vital Sign. Accessed at www.va.gov/PAINMANAGEMENT/docs/TOOLKIT.pdf on 31 May 2013. Google Scholar30. Bates C, Laciak R, Southwick A, Bishoff J. Overprescription of postoperative narcotics: a look at postoperative pain medication delivery, consumption and disposal in urological practice. J Urol. 21011;185:551-5. [PMID: 21168869] CrossrefMedlineGoogle Scholar31. Ballantyne JC, Sullivan MD. Why doctors prescribe opioids to known opioid abusers [Letter]. N Engl J Med. 2013;368:484-5. [PMID: 23363517] CrossrefMedlineGoogle Scholar32. U.S. Food and Drug Administration. About FDA. Accessed at www.fda.gov/aboutfda/whatwedo/default.htm on 31 May 2013. Google Scholar33. U.S. Food and Drug Administration. Drug safety information for healthcare professionals. Accessed at www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/default.htm on 31 May 2013. Google Scholar34. U.S. Food and Drug Administration. FDA introduces new safety measures for extended-release and long-acting opioid medications [news release]. 9 July 2012. Accessed at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm on ???. Google Scholar35. American College of Physicians. Education program for prescribing opioids now available. 15 June 2013. Accessed at www.acponline.org/education_recertification/cme/safe_opioid_prescribing.htm on 30 June 2013. Google Scholar36. U.S. Drug Enforcement Administration. Electronic prescriptions for controlled substances. Docket No. DEA-218, RIN 1117-AA61. Accessed at www.deadiversion.usdoj.gov/fed_regs/rules/2010/fr0331.htm on 31 May 2013. Google Scholar37. U.S. Drug Enforcement Administration. Got drugs? Accessed at www.deadiversion.usdoj.gov/drug_disposal/takeback/index.html on ???. Google Scholar38. U.S. Drug Enforcement Administration. Disposal of controlled substances. Fed Regist. 2012;77:75784-17. Accessed at www.gpo.gov/fdsys/pkg/FR-2012-12-21/pdf/2012-30699.pdf on 31 May 2013. Google Scholar39. Clark T, Eadie J, Kreiner P, Strickler G. Prescription drug monitoring programs: an assessment of the evidence for best practices. The Pew Foundation. September 2012. Accessed at www.pdmpexcellence.org/sites/all/pdfs/Brandeis_PDMP_Report_final.pdf on 31 May 2013. Google Scholar40. Reisman RM, Shenoy PJ, Atherly AJ, Flowers CR. Prescription opioid usage and abuse relationships: an evaluation of state prescription drug monitoring program efficacy. Substance Abuse: Research and Treatment. 2009;3:41-51. CrossrefMedlineGoogle Scholar41. Department of Veterans Affairs. Disclosures to participate in state prescription drug monitoring programs. Interim Final Rule. Fed Regist. 2013;78:9589-93. Accessed at www.gpo.gov/fdsys/pkg/FR-2013-02-11/pdf/2013-03001.pdf on 31 May 2013. Google Scholar42. Federation of State Medical Boards. Model policy on the use of opioid analgesics in the treatment of chronic pain. July 2013. Accessed at www.fsmb.org/pdf/pain_policy_july2013.pdf on 30 September 2013. Google Scholar43. Prescription Drug Abuse Prevention and Treatment Act of 2013 (SB 348). Accessed at www.rockefeller.senate.gov/public/index.cfm/sponsored-legislation on 31 May 2013. Google Scholar44. U.S. Food and Drug Administration. Questions and answers: FDA approves a risk evaluation and mitigation strategy (REMS) for extended-release and long-acting (ER/LA) opioid analgesics. 9 July 2012. Accessed at www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm309742.htm on 31 May 2013. Google Scholar45. National Association of Boards of Pharmacy. lawmakers introduce bill to require abuse-deterrent formulations for opioid pain drugs. 25 July 2012. Accessed at www.nabp.net/news/lawmakers-introduce-bill-to-require-abuse-deterrent-formulations-for-opioid-pain-drugs/ on 31 May 2013. Google Scholar46. Mack MB. Bono Mack, Keating introduce bipartisan bill to require tamper-resistant Rx painkillers [press release]. 19 July 2012. Accessed at http://votesmart.org/public-statement/724329/#.Uou4l_VONak on 31 May 2013. Google Scholar47. Commonwealth of Kentucky. An Act relating to controlled substances and making an appropriation therefore. Accessed at www.lrc.ky.gov/record/12rs/hb4/scs1.doc on 31 May 2013. Google Scholar48. 188th General Court of the Commonwealth of Massachusetts. Session Laws: Chapter 244: An act relative to prescription drug diversion, abuse and addiction. Accessed at www.malegislature.gov/Laws/SessionLaws/Acts/2012/Chapter244 on 31 May 2013. Google Scholar49. The Tennessee Prescription Safety Act. Accessed at http://tn.gov/mental/policy/persc_drug_docs/TN%20Prescription%20Safety%20Act%20of%202012_Public%20Chapter%200880.pdf on 31 May 2013. Google Scholar50. New York Senate Bill 7637. Internet system for Tracking Over-prescribing (I-STOP) Act. 27 August 2012. Accessed at http://legiscan.com/NY/bill/S07637/2011 on 31 May 2013. Google Scholar51. The Florida Senate/CS/CS/HB 7095 — Prescription Drugs. 1 July 2011. Accessed at www.flsenate.gov/Committees/BillSummaries/2011/html/7095HR on 31 May 2013. Google Scholar52. Washington State Register. WSR 11-12-025 Permanent Rules — Department of Health — State of Washington. Medical Quality Assurance Commission. 24 May 2011. Accessed at http://apps.leg.wa.gov/documents/laws/wsr/2011/12/11-12-025.htm on 31 May 2013. Google Scholar53. State of Georgia Medical Board. Rule 360-3-.06. Pain management. Accessed at http://medicalboard.georgia.gov/sites/medicalboard.georgia.gov/files/imported/GCMB/Files/360-3-.06%20Pain%20Management%20Rules.pdf on 31 May 2013. Google Scholar54. O'Reilly K. States try more aggressive Rx opioid controls. American Medical News. 17 October 2011. Accessed at www.ama-assn.org/amednews/2011/10/17/prl21017.htm on 31 May 2013. Google Scholar55. American College of Physicians–American Society of Internal Medicine. Illegal drug abuse and national drug policy. Position Paper. 9 October 1998. Accessed at www.acponline.org/acp_policy/policies/illegal_drug_abuse_national_drug_policy_1998.pdf on 31 May 2013. Google Scholar56. Government Accountability Office. Initial review of the national strategy and drug abuse prevention and treatment programs. GAO-12-744R. 6 July 2012. Accessed at www.gao.gov/products/GAO-12-744R on 31 May 2013. Google Scholar57. 112th U.S. Congress. The Budget Control Act of 2011. Accessed at www.gpo.gov/fdsys/pkg/BILLS-112s365enr/pdf/BILLS-112s365enr.pdf on 31 May 2013. Google Scholar58. Office of the President. Epidemic: responding to America's prescription drug abuse crisis. 2011. Accessed at www.whitehouse.gov/sites/default/files/ondcp/policy-and-research/rx_abuse_plan.pdf on 31 May 2013. Google Scholar59. U.S. Food and Drug Administration. FDA announces safety labeling changes and postmarket study requirements for extended-release and long-acting opioid analgesics [news release]. 10 September 2013. Accessed at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367726.htm on 31 May 2013. Google Scholar60. Cheves J. Urine tests required by new drug law can cost patients hundreds of dollars. Kentucky.com. 27 September 2012. Accessed at www.kentucky.com/2012/09/27/2352733/drug-tests-required-by-new-law.html on 31 May 2013. Google Scholar61. Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152:712-20. [PMID: 20513829] LinkGoogle Scholar62. Fishman SM, Bandman TB, Edwards A, Borsook D. The opioid contract in the management of chronic pain. J Pain Symptom Manage. 1999;18:27-37. [PMID: 10439570] CrossrefMedlineGoogle Scholar63. Payne R, Anderson E, Arnold R, Duensing L, Gilson A, Green C, et al. A rose by any other name: pain contracts/agreements. Am J Bioeth. 2010;10:5-12. [PMID: 21104545] CrossrefMedlineGoogle Scholar64. Farber NJ, Snyder L. The difficult patient: should you end the relationship? What now? An ethics case study. Medscape. 18 October 2009. Accessed at www.medscape.org/viewarticle/706978 on 31 May 2013. Google Scholar65. Institute of Medicine. Preventing Medication Errors: Quality Chasm Series. 2006. Accessed at www.iom.edu/Reports/2006/Preventing-Medication-Errors-Quality-Chasm-Series.aspx on 31 May 2013. Google Scholar66. The Office of the National Coordinator for Health Information Technology. State variation in e-prescribing trends in the United States. ONC Data Brief. November 2012. Accessed at www.healthit.gov/sites/default/files/us_e-prescribingtrends_onc_brief_4_nov2012.pdf on 31 May 2013. Google Scholar67. Surescripts. The national progress report on e-prescribing and interoperable healthcare. Year 2011. Accessed at www.surescripts.com/downloads/npr/National%20Progress%20Report%20on%20E%20Prescribing%20Year%202011.pdf on 31 May 2013. Google Scholar68. Surescripts. Regulatory status of e-prescribing for controlled substances in your state—interactive map. Accessed at www.surescripts.com/about-e-prescribing/e-prescribing-of-controlled-substances/regulatory-status-map.aspx on 31 May 2013. Google Scholar Author, Article, and Disclosure InformationAuthors: Neil Kirschner, PhD; Jack Ginsburg; Lois Snyder Sulmasy, JDAffiliations: From the American College of Physicians, Philadelphia, Pennsylvania.Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations.Financial Support: Financial support for the development of this guideline comes exclusively from the ACP operating budget.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-2209.Corresponding Author: Neil Kirschner, PhD, American College of Physicians, 25 Massachusetts Avenue NW, Suite 700, Washington, DC 20001; e-mail, [email protected]org.Current Author Addresses: Dr. Kirschner and Mr. Ginsburg: American College of Physicians, 25 Massachusetts Avenue NW, Suite 700, Washington, DC 20001.Ms. Snyder Sulmasy: Center for Ethics and Professionalism, American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106.Author Contributions: Conception and design: J. Ginsburg.Analysis and interpretation of the data: N. Kirschner, J. Ginsburg, L. Snyder Sulmasy.Drafting of the article: N. Kirschner, J. Ginsburg, L. Snyder Sulmasy.Critical revision of the article for important intellectual content: N. Kirschner, J. Ginsburg, L. Snyder Sulmasy.Final approval of the article: L. Snyder Sulmasy.Administrative, technical, or logistic support: N. Kirschner.Collection and assembly of data: N. Kirschner, J. Ginsburg.This article was published online first at www.annals.org on 10 December 2013.*This paper, written by Neil Kirschner, PhD; Jack Ginsburg; and Lois Snyder Sulmasy, JD, was developed for the Health and Public Policy Committee of the American College of Physicians. Individuals who served on the Health and Public Policy Committee at the time of the project's approval were: Thomas Tape, MD (Chair); Jacqueline W. Fincher, MD (Co-chair); Vineet Arora, MD; Ankit Bhatia; James F. Bush, MD; Douglas M. DeLong, MD; Susan Glennon, MD; Gregory A. Hood, MD; Mary Newman, MD; Kenneth E. Olive, MD; Shakaib U. Rehman, MD; Zoe Tseng, MD: and Jeffrey G. Wiese, MD. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Dueling Obligations of Opioid Stewardship Phillip Coffin and Caleb Banta-Green The Dueling Obligations of Opioid Stewardship Phillip Coffin and Caleb Banta-Green Prescription Drug Abuse Robert Newman Prescription Drug Abuse J. Walden Retan Prescription Drug Abuse Neil Kirschner and Thomas G. Tape Metrics Cited byOpioid Prescribing Trends After Major Pediatric Ear Surgery: A 12‐Year AnalysisSustaining standardized opioid prescribing practices after pediatric tonsillectomyAbuse/Misuse of Prescription Medications in Older AdultsMacro LevelRecovery, Communities, and the Organized Recovery MovementTrends, Patient and Prescriber Characteristics in Gabapentinoid Use in a Sample of United States Ambulatory Care Visits from 2003 to 2016Review of Nonsurgical Treatment Guidelines for Lower Extremity OsteoarthritisOpioid Use in ChildrenSubstance-Use Disorders in Later LifeOpioid Use After Discharge in Postoperative PatientsDescription and comparison of medication diversion in pharmacies by pharmacists, interns, and pharmacy techniciansOpioid Use in Children and Adolescents After Anterior Cruciate Ligament RepairGeographic Variation in Opioid and Heroin Involved Drug Poisoning Mortality RatesBarriers to integrating the continuum of care for opioid and alcohol use disorders in primary care: A qualitative longitudinal studyDrug involvement in fatal overdosesPrescriptions Written for Opioid Pain Medication in the Veterans Health Administration Between 2000 and 2016Identifying Life-Threatening Admissions for Drug Dependence or Abuse (ILIADDA): Derivation and Validation of a Model.Training internal medicine residents to manage chronic pain and prescription opioid misuseEnhancing the Safe and Effective Management of Chronic Pain in Accountable Care Organization Primary Care Practices in KentuckyTechnical Packages in Injury and Violence Prevention to Move Evidence Into PracticeDrug poisoning deaths in the United States, 1999–2012: a statistical adjustment analysisEffect of opioid prescribing guidelines in primary careInternal medicine resident knowledge, attitudes, and barriers to naloxone prescription in hospital and clinic settingsTrends in opioid prescriptions among children and adolescents in the United StatesRecurring Epidemics of Pharmaceutical Drug Abuse in America: Time for an All-Drug StrategyCorrelates of Self-Stigma among Individuals with Substance Use ProblemsPrescription Opioids in Adolescence and Future Opioid MisuseThe Integration of Care for Mental Health, Substance Abuse, and Other Behavioral Health Conditions into Primary Care: Executive Summary of an American College of Physicians Position PaperRyan A. Crowley, BSJ and Neil Kirschner, PhD, for the Health and Public Policy Committee of the American College of Physicians*A Primer on Prescription Drug Abuse and the Role of the Pharmacy DirectorMost Primary Care Physicians Are Aware Of Prescription Drug Monitoring Programs, But Many Find The Data Difficult To AccessThe ecology of prescription opioid abuse in the USA: geographic variation in patients' use of multiple prescribers ("doctor shopping")Chronic Opioid Therapy Urine Drug Testing in Primary Care: Prevalence and Predictors of Aberrant ResultsFar Too Easy: Opioid Diversion During the Transition from Hospital to Nursing HomeMoving Beyond Misuse and Diversion: The Urgent Need to Consider the Role of Iatrogenic Addiction in the Current Opioid EpidemicOpioid EssentialsThe opioid abuse and misuse epidemic: Implications for pharmacists in hospitals and health systemsOpioid management of painPrescription Drug AbuseJ. Walden Retan, MDPrescription Drug AbuseRobert Newman, MD, MPHOxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse DeterrenceThe Dueling Obligations of Opioid StewardshipPhillip Coffin, MD, MIA and Caleb Banta-Green, PhD 4 February 2014Volume 160, Issue 3Page: 198-200KeywordsDrug abuseDrug regulationDrugsFood and Drug AdministrationMedicareOpioidsPain managementPatientsPrescription drug abuseTherapeutic drug monitoring ePublished: 4 February 2014 Issue Published: 4 February 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...